NCT05313022进行中（未招募）1 期
A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 60 Years and Above
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Proportion of participants achieving seroconversion for SARS-CoV-2 specific IgG binding antibodies..
研究概览
简要总结
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Having understood the contents of the clinical study and ICF, and having signed the ICF.
- •Adults of both genders, 60 years of age and older.
- •Adults who can provide legal proof of identity.
- •SARS-COV-2 antibody screening negative at screening visit.
排除标准
- •Having a clear or suspected allergy to the test vaccine ingredients (including S protein, aluminum hydroxide adjuvant or CpG adjuvant), or have a history of severe allergy to any previous vaccine (such as acute allergic reaction, dyspnea or angioneurotic edema, etc.) (inquiries);
- •Having a history of SARS or MERS infection, or a previous infection of COVID-19 (previous nucleic acid or serum antibody test was positive) (inquiries);
- •Previous vaccination with SARS-CoV-2 vaccine(including SARS-CoV-2 vaccine for clinical trial) or received other vaccines within 28 days prior to the first dose of vaccine;
- •Abnormal skin (such as inflammation, induration, redness and swelling, large area scar, etc.) on both sides of the arm at the vaccination site and affecting the vaccination or safety observation(examination);
- •Axillary body temperature ≥37.3℃ before the first dose vaccination(examination);
- •Safety laboratory abnormal of any of the below:
- •Liver function: ALT or ALT > 1.25*ULN
- •Kidney function: serum creatinine (Cr) > ULN
- •Glycated hemoglobin (HbA1c) ≥ 8.0%
- •Uncontrolled epilepsy or other progressive neurological diseases (inquiries);
- •Immunocompromised or have been diagnosed with Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic lupus erythematosus, SLE, rheumatoid arthritis, inflammatory bowel disease or other autoimmune diseases (inquiries);
- •Asplenia or functional asplenia (inquiries);
- •Having a history of coagulation disorder or abnormal coagulation function (e.g., lack of coagulation factors or thrombocytopenia) and assessed by investigators that are not suitable for the study (inquiry);
- •Having malignant tumor that not been cured clinically and been assessed by investigators as not suitable for the study (inquiry);
- •Having acute diseases or acute onset or poorly controlled chronic diseases(e.g. hypertension patients with blood pressure > 160/100mmHg, diabetes patients with ketoacidosis, etc.) within 14 days before the first dose vaccination and assessed by investigators as not suitable for the study (inquiry);
- •Use of systemic drugs that affect immune function within 6 months prior to the first dose vaccination for a long time (more than 14 consecutive days), such as immunosuppressant, cytotoxic drugs, inhaled corticosteroids (not including allergic rhinitis treated with corticosteroid spray), unless the investigators determines that the drug will not interfere with, limit, or obfuscate the evaluation prescribed by the protocol, or may endanger the safety of the subject (inquiry);
- •Treatment with whole blood, plasma or immunoglobulin within 3 months prior to the first dose(inquiry);
- •Any other factors that, in the investigator's judgment, are inappropriate for participation in the clinical study.
结局指标
主要结局
Proportion of participants achieving seroconversion for SARS-CoV-2 specific IgG binding antibodies..
时间窗: 28 days after each dose
Geometric mean increase (GMI) of SARS-CoV-2 specific IgG binding antibodies.
时间窗: 28 days after each dose
Proportion of participants achieving seroconversion for SARS-CoV-2 neutralising antibody
时间窗: 28 days after each dose
Geometric mean titer (GMT) of SARS-CoV-2 specific IgG binding antibodies.
时间窗: 28 days after each dose
Geometric mean increase (GMI) of SARS-CoV-2 neutralising antibodies
时间窗: 28 days after each dose
Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibody
时间窗: 28 days after each dose
次要结局
- Incidence of solicited adverse events (AEs) after vaccination(30 minutes and 7 days after the first or second vaccination)
- Incidence of unsolicited adverse events (AEs) after vaccination(28 days after the first or second vaccination)
- Proportion of subjects with abnormal markers of hematology, biochemistry, urinalysis, thyroid and coagulation parameters(Day 4 after first or second vaccination)
- Incidence of adverse events (AEs) after vaccination(28 days after the first or second vaccination)
- Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)(up to 12month after last dose vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19COVID-19NCT04982068Shanghai Zerun Biotechnology Co.,Ltd72
已完成
2 期
A Efficacy Study of PRX-00023 in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)NCT00448292Epix Pharmaceuticals, Inc.330
已完成
3 期
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) PatientsPhenylketonuriaNCT01114737BioMarin Pharmaceutical206
已完成
2 期
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT03445195Entasis Therapeutics80
已完成
2 期
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusType1 Diabetes MellitusNCT03117998REMD Biotherapeutics, Inc.154